
Regeneron COVID-19 antibody therapy cuts death risk in hospitalized patients lacking immune response
Fox News
Regeneron’s COVID-19 therapy was found to reduce the risk of death in hospitalized patients who had not mounted their own immune response to the virus by up to 20%, the company said Wednesday
In the current trial, REGEN-COV was shown to rapidly reduce viral levels in hospitalized patients, and lowered risk of death or need for mechanical ventilation, primarily in patients whose immune system did not mount a natural antibody response. The trial showed that adding 8,000 mg of REGEN-COV to usual care was found to reduce all-cause mortality in seronegative patients by 29% compared to usual care alone. The median duration of hospital stay among this patient population was also four days shorter, and the proportion of patients discharged by day 28 was greater.More Related News